Dr. Emily Baumrin, MD

Dr. Baumrin practices at Perelman Center For Advanced Medicine in Philadelphia, Pennsylvania.

Dr. Baumrin's NPI, 1922489111, was assigned on June 12, 2015. Dr. Baumrin graduated from Perelman School of Med at the University of Pennsylvania in 2015. Dr. Baumrin holds Pennsylvania license MD471309.

Dr. Baumrin's primary practice is Perelman Center for Advanced Medicine, at 3400 Civic Center Blvd Fl 2 Fl 2, Philadelphia, PA 19104. The practice phone is (215) 615-4949.

Dr. Baumrin's primary practice is Perelman Center For Advanced Medicine in Philadelphia, Pennsylvania. Dr. Baumrin is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Baumrin to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Baumrin practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Baumrin's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Baumrin is licensed in Pennsylvania.

CMS data shows 445 Medicare services from Dr. Baumrin across 12 procedure codes in 2024, for 148 Medicare patients. Medicare paid $22,549 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 148 Medicare patients who saw Dr. Baumrin in 2024. The largest group is 65 to 74, with 83 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Baumrin's median patient age at 58, with 52% women.

In 2024, Dr. Baumrin wrote 417 Medicare Part D claims for 90 patients. 77% of them were for generic drugs. CMS names the drug for 282 of them, across 11 drugs with 11 or more claims each, at $237,169 in total drug cost. In 2023, CMS named 288 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Baumrin for performance year 2024, reported as part of a group. Dr. Baumrin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Baumrin as offering telehealth. CMS counts 109 procedures of removal of skin lesions by Dr. Baumrin, more than 76% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of skin cancer: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 30 papers to Dr. Baumrin, published from 2017 to 2024. 2022 was the busiest year, with 5. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Skin. Dr. Baumrin has published most often in J Am Acad Dermatol. Dr. Baumrin's most frequent co-authors are Alison W. Loren, MD, Joel M. Gelfand, MD and Ronald Anthony Berna, MD.

CMS Open Payments shows 1 general payment to Dr. Baumrin from 1 drug or device company in 2017. Food and beverage make up the largest share, 100% of the total. Merz North America, Inc. paid the most, $61.

Dr. Baumrin graduated from Perelman School of Med at the University of Pennsylvania in 2015.